A61K31/5575

Drug-polymer conjugate

A polymer-prostaglandin conjugate comprising: a polymer backbone comprising a plurality of moieties of formula (I): where: T represents a triazole moiety; Q is independently selected at each occurrence and may be present or absent and when present represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon; D is selected from prostaglandins; and L is a group of formula (II) wherein R.sup.5 is selected from hydrogen and C.sub.1 to C.sub.6 alkyl; (R) indicates the end of the group bonded to the R group; and (D) indicates the end of the group attached to the group D. ##STR00001##

BIMATOPROST 0.01% SOLUTION COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSTION

The invention relates to topical ophthalmic preparations in eye drops containing bimatoprost as an active ingredient at the concentration of 0.1 mg/ml, wherein the presence of benzalkonium chloride is limited to the indispensable minimum commonly required for its activity as an antimicrobial preservative, i.e. from 50 at 80 ppm, and the bioavailability of the product is ensured by the addition of specific non-ionic surfactants, i.e., poloxamers.

BIMATOPROST 0.01% SOLUTION COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSTION

The invention relates to topical ophthalmic preparations in eye drops containing bimatoprost as an active ingredient at the concentration of 0.1 mg/ml, wherein the presence of benzalkonium chloride is limited to the indispensable minimum commonly required for its activity as an antimicrobial preservative, i.e. from 50 at 80 ppm, and the bioavailability of the product is ensured by the addition of specific non-ionic surfactants, i.e., poloxamers.

PERIPHERALLY ACTING CANNABIDIOL (CBD)-CONTAINING COMPOUNDS AND USES THEREOF FOR ENHANCING FEMALE SEXUAL FUNCTION OR TREATING FEMALE SEXUAL DISORDERS
20220401381 · 2022-12-22 ·

The present disclosure provides peripherally acting cannabidiol (CBD)-containing compositions and methods of using thereof for treating or enhancing female sexual function. In some embodiments, the compositions are provided in the form of a lotion, containing highly CBD-loaded liposomes, which is applied to female genitalia shortly prior to sexual activity.

PERIPHERALLY ACTING CANNABIDIOL (CBD)-CONTAINING COMPOUNDS AND USES THEREOF FOR ENHANCING FEMALE SEXUAL FUNCTION OR TREATING FEMALE SEXUAL DISORDERS
20220401381 · 2022-12-22 ·

The present disclosure provides peripherally acting cannabidiol (CBD)-containing compositions and methods of using thereof for treating or enhancing female sexual function. In some embodiments, the compositions are provided in the form of a lotion, containing highly CBD-loaded liposomes, which is applied to female genitalia shortly prior to sexual activity.

POLYESTERAMIDE COPOLYMERS POSSESSING HIGH GLASS TRANSITION TEMPERATURES
20220396698 · 2022-12-15 ·

Disclosed herein are polyesteramide random copolymers having high glass transition temperatures, methods of forming such polymers, devices, formulations, and medical devices containing such polymers, and methods of treating mammals suffering from various conditions using such polymers in combination with a bioactive agent. In an embodiment, the random copolymers may have a Tg above body temperature, about 37° C., and may achieve a longer release duration, different release kinetics, improved barrier properties, or other benefits over polymers with Tg below 37° C.

POLYESTERAMIDE COPOLYMERS POSSESSING HIGH GLASS TRANSITION TEMPERATURES
20220396698 · 2022-12-15 ·

Disclosed herein are polyesteramide random copolymers having high glass transition temperatures, methods of forming such polymers, devices, formulations, and medical devices containing such polymers, and methods of treating mammals suffering from various conditions using such polymers in combination with a bioactive agent. In an embodiment, the random copolymers may have a Tg above body temperature, about 37° C., and may achieve a longer release duration, different release kinetics, improved barrier properties, or other benefits over polymers with Tg below 37° C.

Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same

Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same

Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same

Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.